Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 08/10/16 -- Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"), has received notification from the Listing Qualifications Department of The NASDAQ Stock Market (the "Staff") indicating that, for the period from June 24, 2016 through August 5, 2016, the closing bid price of the Company''s American Depositary Shares, or ADS, had not been maintained at the minimum required closing bid price of at least US$1.00 per share as required for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule").
Prima has a period of 180-calendar days, or until February 6, 2017, to regain compliance with the Minimum Bid Price Rule. Within any time during the 180-day period the minimum closing bid price per share of the ADSs closes at or above US$1.00 for a minimum of ten consecutive business days, the Staff will provide written notification to the Company that it complies with the Minimum Bid Price Rule and the matter will be closed. Prima''s management is looking into various options available to the Company in order to regain compliance and maintain its continued listing on The NASDAQ Global Market.
Prima''s ADSs will continue to trade uninterrupted on the NASDAQ Global Market under the symbol "PBMD". The Company''s ordinary shares which are traded on the Australian Stock Exchange ("ASX") under the symbol "PRR" are in full compliance with ASX listing requirements and are completely independent of the NASDAQ listing.
In the event that Prima does not regain compliance within the above mentioned period, the Company may be eligible to receive an additional 180-day compliance period; such additional compliance period would be available provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The NASDAQ Capital Market, with the exception of the minimum bid price requirement, based on the Company''s most recent public filings and provides written notice of its intention to cure the minimum bid price deficiency. If it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is not otherwise eligible for the additional compliance period, the Staff would provide written notification to the Company that its ADSs are subject to delisting.
Prima BioMed is listed on the Australian Stock Exchange and on the NASDAQ in the US. Please visit
Matthew Beck
The Trout Group LLC
+1 (646) 378-2933
Mr Matthew Gregorowski
Citadel-MAGNUS
+61 (0) 422 534 755
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.08.2016 - 01:54 Uhr
Sprache: Deutsch
News-ID 1451696
Anzahl Zeichen: 2513
contact information:
Contact person:
Town:
SYDNEY, AUSTRALIA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
